Pulmonology

Diffuse Parenchymal Lung Disease

Questions discussed in this category

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?

Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?

Do you routinely perform genetic testing in patients presenting with pulmonary fibrosis who endorse a family history of fibrotic lung disease?

1 Answer available

Would you consider the use of dual antifibrotic therapy (nintedanib and pirfenidone together) for progressive fibrosing ILD?

3 Answers available

How do you counsel patients regarding prognosis following a diagnosis of IPF?

1 Answer available

Are you using genomic classifiers to diagnose UIP when imaging is indeterminate or suggestive of an alternate diagnosis?

0 Answers available

Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD (ie, fulfilling a possible diagnosis of IPAF) who have not yet demonstrated evidence of a progressive phenotype?

1 Answer available

Is there a role for antifibrotic therapy in post COVID-19 pulmonary fibrosis?

1 Answer available

Which images do you routinely request when ordering a HRCT chest?

1 Answer available

Papers discussed in this category

Eur Respir Rev, 2021 Dec 15

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.

Ann Am Thorac Soc,

Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.

The European respiratory journal, 2015-10

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

American journal of respiratory and critical care medicine, 2011-02-15

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Chest, 2011-07

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

The Lancet. Respiratory medicine, 2017-12

Palliative care in interstitial lung disease: living well.

J Heart Lung Transplant, 2021 Nov

Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

ERJ Open Res, 2019 Jul 08

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.

BMC Pulm Med, 2018 Jan 17

Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey.

Am J Respir Crit Care Med,

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

The European respiratory journal, 2018-08

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

The Lancet. Respiratory medicine, 2018-08

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.

Respir Med, 2011 Sep 13

Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis.

Mayo Clin Proc, 2018 May 24

Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside.

Respirology, 2021 Oct 06

Pulmonary fibrosis associated with telomere-related gene mutations: A complex inheritance.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Pulmonology

Diffuse Parenchymal Lung Disease

Questions discussed in this category

Papers discussed in this category

Related Topics in Pulmonology